TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15992885

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for a maximum of 12 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard medical therapy alone (Control)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Tamsulosin group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study: 12800399

Group type: EXPERIMENTAL
Intervention: Percutaneous suture device
Number of subjects: 167

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 167
Study: 10974130

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg, given at 12-hour intervals)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Ibuprofen (first dose of 10 mg/kg, followed by two doses of 5 mg/kg at 24-hour intervals)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Indomethacin and Ibuprofen
Number of subjects: 148
Study: 8781823

Group type: EXPERIMENTAL
Intervention: Bamiphylline (5 mg.kg‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 36
Study: 8331207

Group type: EXPERIMENTAL
Intervention: Intravenous ceftazidime 1 g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ceftazidime 1 g
Number of subjects: 8
Study: 2867861

Group type: EXPERIMENTAL
Intervention: Almitrine (3 mg/kg single dose, oral)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30400221

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g for 6 days followed by 2 g until the end of the study)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (carboxymethyl cellulose)
Number of subjects: 30
Study: 27543590

Group type: EXPERIMENTAL
Intervention: Web-based self-care support intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Leave-on emollients
Number of subjects: 54
Study: 24962246

Group type: EXPERIMENTAL
Intervention: Hypoxia group (sleep in a normobaric hypoxia chamber)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (sleep in normal conditions)
Number of subjects: 40
Study: 21985440

Group type: EXPERIMENTAL
Intervention: Prefabricated oral appliance (R)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Stabilisation appliance (S)
Number of subjects: 65
Study: 19939717

Group type: EXPERIMENTAL
Intervention: Multi-component pain and stress self-management group intervention (PASS)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Individually administered physical therapy (IAPT)
Number of subjects: 156
Study: 18430606

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16429748

Group type: EXPERIMENTAL
Intervention: Ventilation tubes (VT group)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Watchful waiting (WW group)
Number of subjects: 187
Study: 12860866

Group type: EXPERIMENTAL
Intervention: Nisoldipine 40 mg once daily
Number of subjects: 826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study: 11234739

Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study: 9273229

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) administered subcutaneously at a dose of 2000 U twice weekly (group II)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Repeated hemodialysis without rHuEPO (group I)
Number of subjects: 25
Study: 1353718

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Terbutaline 500 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms vs Formoterol 24 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study: 3917678

Group type: EXPERIMENTAL
Intervention: Recombinant DNA human interferon alpha 2 (IFN alpha 2) 2 million IU m‐2 day‐1, s.c., 3 times a week (schedule 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant DNA human interferon alpha 2 (IFN alpha 2) 50 million IU m‐2 day‐1, i.v., for 5 consecutive days, every 3 weeks (schedule 2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both schedules of IFN alpha 2
Number of subjects: 14
Study: 31227225

Group type: EXPERIMENTAL
Intervention: Explore Transplant @ Home patient‐guided education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explore Transplant @ Home educator‐guided education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study: 30341345

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF), oral dose 300 mg/day, initiated at 24 weeks of gestation and continued to 4 weeks after delivery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no TDF treatment)
Number of subjects: 120
Study: 26675772

Group type: EXPERIMENTAL
Intervention: EAR: 400 IU/d
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: RDA: 600 IU/d
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control: 227 (184-305) IU/d
Number of subjects: 77
Study: 25176317

Group type: EXPERIMENTAL
Intervention: Clinic-based intervention including educational, organizational, and behavioral components administered by trained lay personnel.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group receiving standard coaching without additional intervention components.
Number of subjects: 150
Study: 22574965

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) and fractional photothermolysis (FP) combination treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) alone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fractional photothermolysis (FP) alone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) and fractional photothermolysis (FP) performed 4 weeks apart
Number of subjects: 29
Study: 20860133

Group type: EXPERIMENTAL
Intervention: Simo Decoction Oral Liquid
Number of subjects: 81

Group type: COMPARATOR
Intervention: Neostigmine for acupoint block
Number of subjects: 81
Study: 18479922

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0
Study: 15942768

Group type: COMPARATOR
Intervention: Aerobic exercise group (AE: n=7)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Aerobic and resistance exercise group (AE + RE: n=7)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 21
Study: 11817518

Group type: EXPERIMENTAL
Intervention: Clonidine (up to 800 microg/day)
Number of subjects: 3
Study: 9935127

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/d for 4-5 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Naltrexone treatment
Number of subjects: 22
Study: 7801949

Group type: EXPERIMENTAL
Intervention: i.v. nitroglycerin (300 micrograms‐bolus)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of i.v. nitroglycerin (150 micrograms) and metoclopramide (20‐mg bolus)
Number of subjects: 20
Study: 1980801

Group type: EXPERIMENTAL
Intervention: praziquantel (40 mg/kg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: oxamniquine (60 mg/kg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: metrifonate (two doses of 10 mg/kg bodyweight)
Number of subjects: 160

Group type: COMPARATOR
Intervention: multivitamin preparation
Number of subjects: 160
Study: 91436

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (MCT) with CCNU, methotrexate, and vinblastine for 2 years
Number of subjects: 62

Group type: COMPARATOR
Intervention: Radiotherapy (RT) to the previously involved tumor areas
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy consisting of bleomycin, vinblastine, Adriamycin, and cis‐dichlorodiammineplatinum(II)
Number of subjects: 62
Study: 28240710

Group type: EXPERIMENTAL
Intervention: Intermittent stretching (3 × 30 seconds with 30 seconds rest)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous stretching (90 seconds)
Number of subjects: 16
Study: 26861858

Group type: EXPERIMENTAL
Intervention: IV enoxaparin 0.5 mg/kg
Number of subjects: 165

Group type: COMPARATOR
Intervention: IV unfractionated heparin (UFH)
Number of subjects: 165
Study: 26226074

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study: 23507228

Group type: EXPERIMENTAL
Intervention: Blueberries (300 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control jelly
Number of subjects: 10
Study: 21084650

Group type: EXPERIMENTAL
Intervention: Consuming breakfast
Number of subjects: 21

Group type: COMPARATOR
Intervention: Omitting breakfast
Number of subjects: 21
Study: 19377499

Group type: EXPERIMENTAL
Intervention: Self-expanding stent tailored to shield vulnerable plaques (vProtect Luminal Shield)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Two overlapping drug-eluting stents for the culprit lesion
Number of subjects: 1
Study: 17179343

Group type: EXPERIMENTAL
Intervention: Transthoracic sonography
Number of subjects: 285

Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 285
Study: 15152896

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg (active control)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11563807

Group type: EXPERIMENTAL
Intervention: QSU‐Brief (10 items)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Noncraving questionnaire (scale‐based control)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Time‐based control
Number of subjects: 39
Study: 9553478

Group type: EXPERIMENTAL
Intervention: Impact (test group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Isonitrogenous isocaloric diet (control group)
Number of subjects: 29
Study: 8157729

Group type: EXPERIMENTAL
Intervention: Ketoconazole administration
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 5
Study: 3073625

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg x 2 for 5 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1.5 g x 3 for 3 days, 1 g x 2 days 4 and 5)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 15
Study: 4360398

Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin and cystine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riboflavine and cystine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 0
Study: 30722696

Group type: EXPERIMENTAL
Intervention: Five days of preoperative inspiratory muscle training
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 197
Study: 27782114

Group type: EXPERIMENTAL
Intervention: Severe energy deficit (SEV: -1062±80 kcal per day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate energy deficit (MOD: -633±71 kcal per day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Energy balance (BAL)
Number of subjects: 25
Study: 25167960

Group type: EXPERIMENTAL
Intervention: 1.1 mg folic acid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid
Number of subjects: 37
Study: 23153449

Group type: EXPERIMENTAL
Intervention: RSV fusion protein nanoparticle vaccine (5, 15, 30, and 60 μg with and without aluminum phosphate) administered intramuscularly on day 0 and 30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSV fusion protein nanoparticle vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21607551

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Celecoxib 200 mg once daily
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262
Study: 18222354

Group type: EXPERIMENTAL
Intervention: Carriers of the 719Arg allele of KIF6
Number of subjects: 25283

Group type: COMPARATOR
Intervention: Noncarriers of the 719Arg allele of KIF6
Number of subjects: 25283
Study: 18473981

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS) with cerebral protection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular techniques
Number of subjects: 0
Study: 12702070

Group type: EXPERIMENTAL
Intervention: PUVA and topical calcipotriol
Number of subjects: 22

Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 22
Study: 11126835

Group type: EXPERIMENTAL
Intervention: J-shaped atrial lead
Number of subjects: 208

Group type: COMPARATOR
Intervention: Straight atrial lead
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both leads
Number of subjects: 208
Study: 9193330

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus early CMF (B and D)
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus delayed CMF (C and D)
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Tamoxifen with delayed CMF for ER-negative tumors
Number of subjects: 1266
Study: 1397915

Group type: EXPERIMENTAL
Intervention: Low sodium cleansing solution
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard polyethylene glycol electrolyte solution
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 66
Study: 11540865

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg p.o., twice daily)
Number of subjects: 20
Study: 29845835

Group type: EXPERIMENTAL
Intervention: Self-cross body stretching with scapular stabilization (SS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Self-cross body stretching without scapular stabilization (WS)
Number of subjects: 26
Study: 29761615

Group type: EXPERIMENTAL
Intervention: MK-1293 insulin glargine (Mk-Gla)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Lantus (Sa-Gla)
Number of subjects: 531
Study: 26614676

Group type: EXPERIMENTAL
Intervention: VONCENTO® (50 IU FVIII/kg body weight)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Prophylaxis with VONCENTO®
Number of subjects: 81

Group type: COMPARATOR
Intervention: Biostate‐RP (reference product)
Number of subjects: 81
Study: 25348207

Group type: EXPERIMENTAL
Intervention: Educational materials (board game, video, or booklet)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Entertaining material (same format type as educational materials)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No material (control group)
Number of subjects: 125
Study: 22257841

Group type: EXPERIMENTAL
Intervention: Nonfatal outcomes adjudicated by three cardiology specialists
Number of subjects: 5837

Group type: EXPERIMENTAL
Intervention: Fatal outcomes adjudicated by three cardiology specialists
Number of subjects: 5837
Study: 21135294

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 142
Study: 17927576

Group type: EXPERIMENTAL
Intervention: Myristyl nicotinate (MN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retinoic acid therapy
Number of subjects: 0
Study: 15784032

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg, three times daily for 6 months)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (identical appearance to indomethacin, for 6 months)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 12487503

Group type: EXPERIMENTAL
Intervention: Fusafungine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 10323814

Group type: EXPERIMENTAL
Intervention: Withdrawal from alcohol consumption for 1 month before operation (disulfiram controlled)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous drinking
Number of subjects: 42
Study: 8942899

Group type: EXPERIMENTAL
Intervention: Limited SMAS (lateral SMASectomy)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Conventional SMAS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Extended SMAS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Composite rhytidectomy
Number of subjects: 21
Study: 1754846

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS), two tablets twice daily for 4 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 71
Study: 7022484

Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate (300 mg per day)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Aspirin (3.6 g per day)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 31977643

Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Loading (ITL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Neck Flexion (INF)
Number of subjects: 12
Study: 31188026

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 28951663

Group type: EXPERIMENTAL
Intervention: 800 mg i.v. ibuprofen
Number of subjects: 42

Group type: COMPARATOR
Intervention: saline without ibuprofen
Number of subjects: 42
Study: 27290966

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-dose remifentanil infusion
Number of subjects: 30
Study: 24418652

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Community Treatment by Experts (CTBE)
Number of subjects: 101
Study: 22954842

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE) administered for 10 treatment sessions over 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal Attention (MA) control group for 5 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0
Study: 19651336

Group type: EXPERIMENTAL
Intervention: 0.016-in CuNiTi wire
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.016-in NiTi wire
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Severe crowding (>5 on the irregularity index)
Number of subjects: 60
Study: 16824689

Group type: EXPERIMENTAL
Intervention: Abstinent smokers
Number of subjects: 44

Group type: COMPARATOR
Intervention: Satiated smokers
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Negative clips
Number of subjects: 44
Study: 15058627

Group type: EXPERIMENTAL
Intervention: Computer-controlled delivery of local anesthetic (AMSA injection)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Syringe delivery of local anesthetic (GP and NP injections)
Number of subjects: 20
Study: 12514752

Group type: EXPERIMENTAL
Intervention: Chest sonography
Number of subjects: 55

Group type: COMPARATOR
Intervention: Ventilation/perfusion scintigraphy
Number of subjects: 55
Study: 9801179

Group type: EXPERIMENTAL
Intervention: Ondansetron hydrochloride, 4 mg intravenously
Number of subjects: 78

Group type: COMPARATOR
Intervention: Prochlorperazine maleate, 10 mg intramuscularly
Number of subjects: 78
Study: 8752413

Group type: EXPERIMENTAL
Intervention: Syringo-subarachnoid shunt (S-S shunt)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Foramen magnum decompression (FMD)
Number of subjects: 80
Study: 2243259

Group type: EXPERIMENTAL
Intervention: Formal health status reports every 3 months over 1 year
Number of subjects: 1920

Group type: COMPARATOR
Intervention: Attention placebo
Number of subjects: 1920

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1920
Study: 345336

Group type: EXPERIMENTAL
Intervention: Lidocaine added to contrast medium
Number of subjects: 28

Group type: COMPARATOR
Intervention: Contrast medium alone
Number of subjects: 28
Study: 31987233

Group type: EXPERIMENTAL
Intervention: Sucrose (0.5 ml of oral 24% sucrose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Music (lullaby music)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of sucrose and music
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (headphones without music and sterile water)
Number of subjects: 120
Study: 30478984

Group type: EXPERIMENTAL
Intervention: Philips Zoom WhiteSpeed (PZW)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Ultradent Opalescence Boost PF (UOB)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Philips Sonicare power toothbrush (SDC)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 135
Study: 26691576

Group type: EXPERIMENTAL
Intervention: Adjunctive sarcosine (2 g/day) plus benzoate (1 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sarcosine (2 g/day)
Number of subjects: 0
Study: 25291409

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.25 mg/kg/d for 7 days
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 198
Study: 22652007

Group type: COMPARATOR
Intervention: GTR-DFDBA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SCTG
Number of subjects: 12
Study: 21541462

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccine administration (4 mg/dose)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccine administration (40 mg/dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccine administration
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccine administration
Number of subjects: 31
Study: 19516157

Group type: EXPERIMENTAL
Intervention: Combined endurance and strength training (ES)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 93
Study: 17503990

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15521845

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18